Different molecular levels of post-induction minimal residual disease may predict hematopoietic stem cell transplantation outcome in adult Philadelphia-negative acute lymphoblastic leukemia

摘要

Minimal residual disease (MRD) is a powerful indicator of the risk of relapse in adult acute lymphoblastic leukemia (ALL), 1 used for the risk-oriented application of allogeneic stem cell transplantation (allo-SCT) in patients who remain MRD-positive (MRD+) following induction and consolidation chemotherapy. 2 , 3 , 4 Although allo-SCT is less effective in MRD+ state, 5 , 6 , 7 correlations between post-induction quantitative MRD ranges and SCT outcome have not been clearly defined. This would allow an early identification of MRD+ patients at higher risk of posttransplantation failure, for whom a closer MRD monitoring and other therapies could be recommended before and after allo-SCT.